Patents by Inventor Markus Ahlheim

Markus Ahlheim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Octreotide Depot Formulation with Constantly High Exposure Levels
    Publication number: 20240082148
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: April 27, 2023
    Publication date: March 14, 2024
    Inventors: Markus AHLHEIM, Holger PETERSEN
  • SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
    Publication number: 20220296675
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs).
    Type: Application
    Filed: June 7, 2022
    Publication date: September 22, 2022
    Inventors: Holger Petersen, Markus Ahlheim
  • Octreotide Depot Formulation with Constantly High Exposure Levels
    Publication number: 20210161806
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Inventors: Markus Ahlheim, Holger Petersen
  • SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
    Publication number: 20200206306
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAs).
    Type: Application
    Filed: March 10, 2020
    Publication date: July 2, 2020
    Inventors: Holger Petersen, Markus Ahlheim
  • Octreotide depot formulation with constantly high exposure levels
    Publication number: 20190209462
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: March 14, 2019
    Publication date: July 11, 2019
    Inventors: Markus Ahlheim, Holger Petersen
  • Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide Polymers
    Publication number: 20180140662
    Abstract: The present invert on relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: January 17, 2018
    Publication date: May 24, 2018
    Inventors: Holger Petersen, Markus Ahlheim
  • OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS
    Publication number: 20180036230
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: October 19, 2017
    Publication date: February 8, 2018
    Inventors: Markus Ahlheim, Holger Petersen
  • OCTREOTIDE DEPOT FORMULATION WITH CONSTANTLY HIGH EXPOSURE LEVELS
    Publication number: 20170143791
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: January 10, 2017
    Publication date: May 25, 2017
    Inventors: Markus Ahlheim, Holger Petersen
  • Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers
    Publication number: 20160120935
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: December 22, 2015
    Publication date: May 5, 2016
    Applicant: Novartis AG
    Inventors: Holger Petersen, Markus Ahlheim
  • Octreotide depot formulation with constantly high exposure levels
    Publication number: 20160089336
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: December 9, 2015
    Publication date: March 31, 2016
    Applicant: Novartis AG
    Inventors: Markus Ahlheim, Holger Petersen
  • Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
    Patent number: 8999390
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 7, 2015
    Assignee: Novartis AG
    Inventors: Holger Petersen, Markus Ahlheim
  • Sustained Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers
    Publication number: 20150037420
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Novartis AG
    Inventors: Holger Petersen, Markus Ahlheim
  • Octreotide Depot Formulation with Constantly High Exposure Levels
    Publication number: 20140363513
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: August 25, 2014
    Publication date: December 11, 2014
    Applicant: Novartis AG
    Inventors: Markus Ahlheim, Holger Petersen
  • Organic compounds
    Patent number: 8815293
    Abstract: A depot formulation comprising iloperidone and a biodegradable, biocompatible polymer. Preferably, the polymer is a star polymer.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: August 26, 2014
    Assignee: Novartis AG
    Inventors: Markus Ahlheim, Rolf Loeffler
  • Injectable depot formulation comprising crystals of iloperidone
    Patent number: 8614232
    Abstract: An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Dierk Wieckhusen, Alexandra Glausch, Markus Ahlheim
  • INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE
    Publication number: 20130012542
    Abstract: An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Dierk Wieckhusen, Alexandra Glausch, Markus Ahlheim
  • Injectable depot formulation comprising crystals of iloperidone
    Patent number: 8293765
    Abstract: An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: October 23, 2012
    Assignee: Novartis AG
    Inventors: Dierk Wieckhusen, Alexandra Glausch, Markus Ahlheim
  • SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND THREE LINEAR POLYLACTIDE-CO-GLYCOLIDE POLYMERS
    Publication number: 20120226224
    Abstract: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
    Type: Application
    Filed: May 15, 2012
    Publication date: September 6, 2012
    Inventors: Holger Petersen, Markus Ahlheim
  • MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES
    Publication number: 20120214749
    Abstract: Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 23, 2012
    Applicant: NOVARTIS AG
    Inventors: Markus Ahlheim, Michael Ausborn, Olivier Lambert, Marc Riemenschnitter
  • Injectable depot formulation comprising crystals of iloperidone
    Patent number: 8227488
    Abstract: An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: July 24, 2012
    Assignee: Novartis AG
    Inventors: Dierk Wieckhusen, Alexandra Glausch, Markus Ahlheim